Unilife Corporation designs, manufactures, and supplies injectable drug delivery systems in the United States. The majority of the company’s products are designed for sale directly to pharmaceutical and biotechnology companies who are expected to supply them as drug-device combination products, pre-filled and ready for administration by patients or health-care providers. Product Platforms The company has developed a portfolio of injectable drug delivery systems that are designed for use with a range of injectable therapies. Existing and prospective customers can select from a series of platform-based technologies, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. Wearable Injectors The company’s wearable injector portfolio is designed to support pharmaceutical demand for disposable drug delivery systems that could be worn on the body of a patient over pre-configured periods, such as varius minutes or several hours during the subcutaneous injection of a measured dose of an injectable therapy. All of the company’s wearable injector products are designed to allow pharmaceutical and biotechnology companies to supply their therapies to end users in a pre-filled, pre-assembled and ready-to inject format for self-injection to minimize disruption to normal daily life during the period of therapy administration. This portfolio includes the Precision-Therapy platform of bolus injection devices and the Flex-Therapy platform of basal infusion devices that are designed to contain and deliver injectable therapies with a measured dose volume between 2mL and 10mL. The company has also created smaller volume wearable injector platforms, which are designed to improve the containment, delivery and use of biologics with dose volumes less than 2mL that might otherwise be administered in prefilled syringes or disposable auto injectors. The company’s Imperium platform is designed to deliver concentrated insulins up to U-500 to help patients to gain better control over their blood glucose levels. Each of the company’s platforms utilize standard materials, such as glass cartridges and elastomers. Products could be pre-configured to control the duration, rate and volume of dose delivery for an injectable therapy to the target patient. The company’s wearable injector products require three device-related simple user steps to commence the therapy, which includes peel off the adhesive liner, stick the product onto the body and click the button to commence the injection. The company’s wearable injectors could be configured to include a soft catheter that is automatically inserted into the body with the needle, and the catheter remaining in the body following retraction of the needle, enabling drug delivery and supporting patient comfort during drug delivery without an exposed needle. Other Drug Delivery Systems The company has developed various product platforms, including its Unifill platform of pre-filled syringes, its LISA smart reusable and RITA disposable auto-injectors, its EZMix platform of drug reconstitution delivery systems, and its Ocu-ject, Ocu-mix, and Depot-ject ocular delivery systems. The company’s Micro-Ject delivery system is designed to optimize the delivery of therapies with microliter doses that are unsuited to conventional device technologies, including to the eye or other organs. Research and Development For the fiscal year ended June 30, 2016, the company incurred research and development expenses of $43.2 million. Sales and Marketing The company’s existing and prospective customers are pharmaceutical and biotechnology companies that develop and market a range of injectable therapies to treat various acute, chronic and rare diseases. The majority of these existing and prospective customers are large, multinational businesses based in the U.S., Europe and Japan. The company’s customers typically have various injectable therapies, such as biologics, including monoclonal antibodies, that are either approved or in clinical development an
unilife corp-cdi (UNISZ:OTC US)
250 Cross Farm Lane
York, PA 17406
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for UNISZ.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact UNILIFE CORP-CDI, please visit www.unilife.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.